The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis

被引：13

作者：

Merza, Nooraldin ^{[1
]}

Akram, Moeez ^{[2
,9
]}

Mengal, Aqsa ^{[3
]}

Rashid, Ahmed Mustafa ^{[4
]}

Mahboob, Anber ^{[5
]}

Faryad, Mawwra ^{[6
]}

Fatima, Zairah ^{[6
]}

Ahmed, Muhammad ^{[7
]}

Ansari, Saad Ali ^{[8
]}

机构：

[1] Univ Toledo, Dept Internal Med, Toledo, OH USA

[2] Allama Iqbal Med Coll, Lahore, Pakistan

[3] Fatima Jinnah Med Univ, Lahore, Pakistan

[4] Jinnah Sindh Med Univ, Karachi, Pakistan

[5] Sharif Med & Dent Coll, Lahore, Pakistan

[6] King Edward Med Univ, Lahore, Pakistan

[7] Shaheed Mohtarma Benazir Bhutto Med Coll, Karachi, Pakistan

[8] Univ Calif Riverside, Riverside Sch Med, Dept Internal Med, Riverside, CA USA

[9] 161,St 5,Southern Block,Phase 1,Raiwind Rd, Lahore, Pakistan

来源：

CURRENT PROBLEMS IN CARDIOLOGY | 2023年 / 48卷 / 05期

关键词：

GLUCAGON-LIKE PEPTIDE-1; EJECTION FRACTION; LIRAGLUTIDE; DYSFUNCTION; INFUSION; OUTCOMES;

D O I：

10.1016/j.cpcardiol.2023.101602

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Evaluation of glucagon-like peptide-1 recep-tor agonists (GLP-1 RAs) usage in heart failure (HF) patients with or without type 2 diabetes mellitus (T2DM) could be proven to be a critical breakthrough in treatment options available for these patients. Our study focuses on understanding the safety and efficacy of GLP-1 RAs in this patient population by pooling the data from 9 randomized controlled trials (RCTs) com-prising 871 subjects. As compared with the placebo, GLP-1 RAs did not improve major adverse cardiovas-cular events (MACE) which include cardiovascular (CV) mortality and heart failure (HF) hospitalizations, our primary outcome. CV mortality (RR = 1.03, 95% CI = 0.56-1.88, P = 0.92) and HF hospitalizations (RR = 1.18, 95%CI = 0.93-1.51, P = 0.18). Similarly, GLP-1 RAs did not improve our secondary findings of left ventricular ejection fraction (LVEF) and 6-minute walk test (6MWT). LVEF (RR = 1.96, 95%CI = -0.16-4.07, P = 0.07) or 6 MWT (RR = 8.43, 95% CI = -2.69-19.56, P = 0.14). This meta-analysis shows that GLP-1 RAs do not improve cardiovascular outcomes in HF patients with or without T2DM. (Curr Probl Cardiol 2023;48:101602.)

引用

页数：13

共 22 条

[1]

[Anonymous], 2020, LANCET DIABETES ENDO, V8, pe2

[2] Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways [J].

Ban, Kiwon ;

Noyan-Ashraf, M. Hossein ;

Hoefer, Judith ;

Bolz, Steffen-Sebastian ;

Drucker, Daniel J. ;

Husain, Mansoor .

CIRCULATION, 2008, 117 (18) :2340-2350

[3] Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis [J].

Butler, Javed ;

Usman, Muhammad Shariq ;

Khan, Muhammad Shahzeb ;

Greene, Stephen J. ;

Friede, Tim ;

Vaduganathan, Muthiah ;

Filippatos, Gerasimos ;

Coats, Andrew J. Stewart ;

Anker, Stefan D. .

ESC HEART FAILURE, 2020, 7 (06) :3298-3309

[4] Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction [J].

Chen, Wei-Ren ;

Shen, Xue-Qin ;

Zhang, Ying ;

Chen, Yun-Dai ;

Hu, Shun-Ying ;

Qian, Geng ;

Wang, Jing ;

Yang, Jun-Jie ;

Wang, Zhi-Feng ;

Tian, Feng .

ENDOCRINE, 2016, 52 (03) :516-526

[5] Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial [J].

Gerstein, Hertzel C. ;

Colhoun, Helen M. ;

Dagenais, Gilles R. ;

Diaz, Rafael ;

Lakshmanan, Mark ;

Pais, Prem ;

Probstfield, Jeffrey ;

Riesmeyer, Jeffrey S. ;

Riddle, Matthew C. ;

Ryden, Lars ;

Xavier, Denis ;

Atisso, Charles Messan ;

Dyal, Leanne ;

Hall, Stephanie ;

Rao-Melacini, Purnima ;

Wong, Gloria ;

Avezum, Alvaro ;

Basile, Jan ;

Chung, Namsik ;

Conget, Ignacio ;

Cushman, William C. ;

Franek, Edward ;

Hancu, Nicolae ;

Hanefeld, Markolf ;

Holt, Shaun ;

Jansky, Petr ;

Keltai, Matyas ;

Lanas, Fernando ;

Leiter, Lawrence A. ;

Lopez-Jaramillo, Patricio ;

Cardona Munoz, Ernesto German ;

Pirags, Valdis ;

Pogosova, Nana ;

Raubenheimer, Peter J. ;

Shaw, Jonathan E. ;

Sheu, Wayne H-H ;

Temelkova-Kurktschiev, Theodora .

LANCET, 2019, 394 (10193) :121-130

[6] Glucagon-Like Peptide-1-Mediated Cardioprotection Does Not Reduce Right Ventricular Stunning and Cumulative Ischemic Dysfunction After Coronary Balloon Occlusion [J].

Giblett, Joel P. ;

Axell, Richard G. ;

White, Paul A. ;

Aetesam-Ur-Rahman, Muhammad ;

Clarke, Sophie J. ;

Figg, Nicola ;

Bennett, Martin R. ;

West, Nick E. J. ;

Hoole, Stephen P. .

JACC-BASIC TO TRANSLATIONAL SCIENCE, 2019, 4 (02) :222-233

[7] Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure [J].

Halbirk, Mads ;

Norrelund, Helene ;

Moller, Niels ;

Holst, Jens Juul ;

Schmitz, Ole ;

Nielsen, Roni ;

Nielsen-Kudsk, Jens Erik ;

Nielsen, Soren Steen ;

Nielsen, Torsten Toftegaard ;

Eiskjaer, Hans ;

Botker, Hans Erik ;

Wiggers, Henrik .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2010, 298 (03) :H1096-H1102

[8] Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial [J].

Hernandez, Adrian F. ;

Green, Jennifer B. ;

Janmohamed, Salim ;

D'Agostino, Ralph B., Sr. ;

Granger, Christopher B. ;

Jones, Nigel P. ;

Leiter, Lawrence A. ;

Rosenberg, Anne E. ;

Sigmon, Kristina N. ;

Somerville, Matthew C. ;

Thorpe, Karl M. ;

McMurray, John J. V. ;

Del Prato, Stefano .

LANCET, 2018, 392 (10157) :1519-1529

[9] Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes [J].

Holman, Rury R. ;

Bethel, M. Angelyn ;

Mentz, Robert J. ;

Thompson, Vivian P. ;

Lokhnygina, Yuliya ;

Buse, John B. ;

Chan, Juliana C. ;

Choi, Jasmine ;

Gustavson, Stephanie M. ;

Iqbal, Nayyar ;

Maggioni, Aldo P. ;

Marso, Steven P. ;

Ohman, Peter ;

Pagidipati, Neha J. ;

Poulter, Neil ;

Ramachandran, Ambady ;

Zinman, Bernard ;

Hernandez, Adrian F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (13) :1228-1239

[10] Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [J].

Kristensen, Soren L. ;

Rorth, Rasmus ;

Jhund, Pardeep S. ;

Docherty, Kieran F. ;

Sattar, Naveed ;

Preiss, David ;

Kober, Lars ;

Petrie, Mark C. ;

McMurray, John J. V. .

LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (10) :776-785

← 1 2 3 →